In section Market Quotes

Savara Falls 17% as FDA Misses Molgramostim Review Target

Savara shares fell 17% to $4.31 in late-morning trading Friday after the company said the FDA would not meet its target date for reviewing its application for molgramostim, an inhaled treatment for a rare lung disease.

Savara Falls 17% as FDA Misses Molgramostim Review Target

The shares have slumped 28% this year. Savara said the agency told it that it would miss the target action date of Sunday, Nov. 22, for the biologics license application.

The FDA review is continuing, and the agency has not provided a revised action date, according to Savara.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!